Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov 22;61(12):e01763-17.
doi: 10.1128/AAC.01763-17. Print 2017 Dec.

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals

Sergio Serrano-Villar  1 , Giorgia Caruana  2 , Alexander Zlotnik  3 , José A Pérez-Molina  4 , Santiago Moreno  4
Affiliations
Clinical Trial

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals

Sergio Serrano-Villar et al. Antimicrob Agents Chemother. .

Abstract

A low CD4/CD8 ratio during treated HIV infection reflects heightened immune activation and predicts death. The effects of different antiretroviral therapy regimens on CD4/CD8 ratio recovery remains unclear. We performed a post hoc analysis of the MERIT study, a randomized, double-blind trial of maraviroc versus efavirenz in combination with zidovudine-lamivudine in treatment-naive HIV-infected individuals. We found higher rates of CD4/CD8 ratio normalization with efavirenz, which was driven by a greater CD8+ T-cell decline.

Keywords: CD4/CD8 ratio; HIV; T cells; T-cell activation; antiretroviral therapy; efavirenz; maraviroc.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Kaplan-Meier analysis for the comparison of time to CD4/CD8 normalization at cutoffs of 0.4 (a) and 1.0 (b).
FIG 2
FIG 2
Longitudinal trajectories of the CD4/CD8 ratio (a), the CD4+ T-cell count (b), and the CD8+ T-cell count (c). The lines represent estimated mean values over time from GEE for each group with the 95% confidence intervals.
See this image and copyright information in PMC

References

    1. Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. 2016. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 73:39–46. doi:10.1097/QAI.0000000000001014. - DOI - PMC - PubMed
    1. Deeks SG. 2011. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155. doi:10.1146/annurev-med-042909-093756. - DOI - PMC - PubMed
    1. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, Lederman MM, Landay AL. 2014. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 210:1248–1259. doi:10.1093/infdis/jiu254. - DOI - PMC - PubMed
    1. Sainz T, Serrano-Villar S, Díaz L, González-Tomé MI, Gurbindo MD, de José MI, Mellado MJ, Ramos JT, Zamora J, Moreno S, Muñoz-Fernández MA. 2013. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 27:1513–1516. doi:10.1097/QAD.0b013e32835faa72. - DOI - PubMed
    1. Serrano-Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, Ferre AL, Hayes TL, Somsouk M, Hsue PY, Van Natta ML, Meinert CL, Lederman MM, Hatano H, Jain V, Huang Y, Hecht FM, Martin JN, McCune JM, Moreno S, Deeks SG. 2014. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 10:e1004078. doi:10.1371/journal.ppat.1004078. - DOI - PMC - PubMed

Publication types

MeSH terms